预测前列腺癌68Ga-PSMA-11 PET阳性骨病灶为转移性疾病的因素
回顾性纳入56例前列腺癌患者,评估68Ga-PSMA-11 PET对骨转移的诊断准确性,并用半定量指标优化骨摄取判读。PSMA RADS评分≥4、SUVmax≥4.1及病灶/血池SUVmax比值≥2.11等截断值在良恶性病灶间差异有统计学意义(P<0.005)。
要点
- 56例中13例(22.8%)为假阳性骨病灶,43例(76.8%)为真阳性骨病灶。
- PSMA RADS≥4、SUVmax≥4.1、病灶/血池比值≥2.11等截断值可区分良恶性(P<0.005)。
- 病灶/血池SUVmax比值>2.2支持图像判读,病灶检出率和特异性优于PSMA RADS视觉判读。
核心结论
- PSMA RADS评分、SUVmax及病灶/血池SUVmax比值有助于区分68Ga-PSMA-11 PET上的良恶性骨病灶。
- 病灶/血池SUVmax比值>2.2是支持图像判读的合理参数,其病灶检出率和特异性优于PSMA RADS视觉判读。
研究设计与样本
- 回顾性纳入56例前列腺癌患者(18例前列腺切除术前,38例生化复发),均接受68Ga-PSMA-11 PET/MRI或PET/CT检查且存在骨性PSMA配体摄取。
- 由委员会认证的核放射科医师回顾病历,基于复合终点判定真阳性或假阳性。
主要发现
- 56例中13例(22.8%)为假阳性骨68Ga-PSMA-11表现,43例(76.8%)为真阳性骨68Ga-PSMA-11表现。
- 22例(39%)有1个骨病灶,18例(32%)有2-4个病灶,16例(29%)有5个或以上病灶。
- 良恶性病灶间差异有统计学意义(P<0.005)的截断值为PSMA RADS评分至少4、SUVmax至少4.1、病灶/血池SUVmax比值至少2.11、病灶/肝脏至少0.55、病灶/骨至少4.4。
- 上述指标对应的恶性病灶检出率分别为80%、93%、89%、21%、89%,特异性分别为73%、73%、73%、93%、60%。
关键数值与推荐
- PSMA RADS评分至少4为区分良恶性骨病灶的截断值,恶性病灶检出率80%,特异性73%。
- SUVmax至少4.1为截断值,恶性病灶检出率93%,特异性73%。
- 病灶/血池SUVmax比值至少2.11为截断值,恶性病灶检出率89%,特异性73%。
- 病灶/肝脏SUVmax比值至少0.55为截断值,恶性病灶检出率21%,特异性93%。
- 病灶/骨SUVmax比值至少4.4为截断值,恶性病灶检出率89%,特异性60%。
临床怎么用
- 作者认为PSMA RADS评分、SUVmax和病灶/血池SUVmax比值可帮助区分良恶性骨病灶。
- 作者认为病灶/血池SUVmax比值>2.2是支持图像判读的合理参数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone is the most common site of distant metastatic spread in prostate adenocarcinoma. Prostate-specific membrane antigen (PSMA) uptake has been described in both benign and malignant bone lesions, which can lead to false-positive findings on 68Ga-PSMA-11 PET. The purpose of this study was to evaluate the diagnostic accuracy of 68Ga-PSMA-11 PET for osseous prostate cancer metastases and improve bone uptake interpretation using semiquantitative metrics. Methods: Fifty-six prostate cancer patients (18 before prostatectomy and 38 with biochemical recurrence) who underwent 68Ga-PSMA-11 PET/MRI or PET/CT examinations with osseous PSMA-ligand uptake were included in the study. Medical records were reviewed retrospectively by board-certified nuclear radiologists to determine true or false positivity based on a composite endpoint. For each avid osseous lesion, we measured biologic volume; size; PSMA Reporting and Data System (RADS) rating; SUVmax; and ratio of lesion SUVmax to liver, blood pool, and background bone SUVmax Differences between benign and malignant lesions were evaluated for statistical significance, and cutoffs for these parameters were determined to maximize diagnostic accuracy. Results: Among 56 participants, 13 (22.8%) had false-positive osseous 68Ga-PSMA-11 findings and 43 (76.8%) had true-positive osseous 68Ga-PSMA-11 findings. Twenty-two patients (39%) had 1 osseous lesion, 18 (32%) had 2-4 lesions, and 16 (29%) had 5 or more lesions. Cutoffs resulting in statistically significant (P < 0.005) differences between benign and malignant lesions were a PSMA RADS rating of at least 4, an SUVmax of at least 4.1, and SUVmax ratios of at least 2.11 for lesion to blood pool, at least 0.55 for lesion to liver, and at least 4.4 for lesion to bone. These measurements corresponded to a lesion-based 68Ga-PSMA-11 PET lesion detection rate of 80%, 93%, 89%, 21%, and 89%, respectively, for malignancy, and a specificity of 73%, 73%, 73%, 93%, and 60%, respectively. Conclusion: PSMA RADS rating, SUVmax, and SUVmax ratio for lesion to blood pool can help differentiate benign from malignant lesions on 68Ga-PSMA-11 PET. An SUVmax ratio of more than 2.2 for lesion to blood pool is a reasonable parameter to support image interpretation and presented a superior lesion detection rate and specificity when compared with visual interpretation by PSMA RADS. These parameters hold clinical value by improving diagnostic accuracy for metastatic prostate cancer on 68Ga-PSMA-11 PET/MRI and PET/CT.
引用
- Chiu LW, Lawhn-Heath C, Behr SC, et al. Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer. J Nucl Med. 2020. PMID: 32303599. doi:10.2967/jnumed.119.241174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。